Literature DB >> 14622501

Tadalafil in the treatment of erectile dysfunction.

Anthony J Bella1, Gerald B Brock.   

Abstract

Oral phosphodiesterase-5 inhibitors have emerged as the preferred first-line treatment for erectile dysfunction worldwide because of patient convenience, efficacy, and safety. Clinical trials have shown that tadalafil significantly enhances erectile function across a wide range of etiologies and provides a prolonged period of effectiveness independent of food or alcohol. In this review, the pharmacokinetic and pharmacodynamic characteristics, efficacy, and safety of tadalafil are discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14622501     DOI: 10.1007/s11934-003-0029-8

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  23 in total

Review 1.  The worldwide prevalence and epidemiology of erectile dysfunction.

Authors:  J B McKinlay
Journal:  Int J Impot Res       Date:  2000-10       Impact factor: 2.896

2.  Nitric oxide as a mediator of relaxation of the corpus cavernosum.

Authors:  I Saenz de Tejada
Journal:  N Engl J Med       Date:  1992-06-11       Impact factor: 91.245

Review 3.  Cyclic GMP and mechanisms of vasodilation.

Authors:  T M Lincoln
Journal:  Pharmacol Ther       Date:  1989       Impact factor: 12.310

4.  Sexual function in men with diabetes type 2: association with glycemic control.

Authors:  J H Romeo; A D Seftel; Z T Madhun; D C Aron
Journal:  J Urol       Date:  2000-03       Impact factor: 7.450

5.  Diabetes and vascular impotence: does insulin dependence increase the relative severity?

Authors:  M J Metro; G A Broderick
Journal:  Int J Impot Res       Date:  1999-04       Impact factor: 2.896

6.  The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial.

Authors:  H Porst; R Rosen; H Padma-Nathan; I Goldstein; F Giuliano; E Ulbrich; T Bandel
Journal:  Int J Impot Res       Date:  2001-08       Impact factor: 2.896

7.  Effects of tadalafil on erectile dysfunction in men with diabetes.

Authors:  Iñigo Sáenz de Tejada; Greg Anglin; James R Knight; Jeffrey T Emmick
Journal:  Diabetes Care       Date:  2002-12       Impact factor: 19.112

Review 8.  Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction.

Authors:  S Uckert; A Küthe; C G Stief; U Jonas
Journal:  World J Urol       Date:  2001-02       Impact factor: 4.226

9.  Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial.

Authors:  Hartmut Porst; Harin Padma-Nathan; François Giuliano; Greg Anglin; Lucio Varanese; Raymond Rosen
Journal:  Urology       Date:  2003-07       Impact factor: 2.649

Review 10.  Towards an understanding of the mechanism of action of cyclic AMP and cyclic GMP in smooth muscle relaxation.

Authors:  T M Lincoln; T L Cornwell
Journal:  Blood Vessels       Date:  1991
View more
  2 in total

Review 1.  Sexual dysfunction in the older woman: an overview of the current understanding and management.

Authors:  Kathleen E Walsh; Jennifer R Berman
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

2.  PDE5 Inhibitors as Potential Tools in the Treatment of Cystic Fibrosis.

Authors:  Sabrina Noel; Barbara Dhooghe; Teresinha Leal
Journal:  Front Pharmacol       Date:  2012-09-18       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.